Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Merck Sharp & Dohme LLC
Related studies linked through entity extraction aliases.
Cabozantinib and Pembrolizumab in Metastatic Pancreas
- Status
- COMPLETED
- Phase
- PHASE2
Longer-Acting PrEP in Transgender and Gender Diverse Texans
- Status
- COMPLETED
- Phase
- N/A
Letermovir for CMV Prevention After Lung Transplantation
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)
- Status
- TERMINATED
- Phase
- PHASE1
Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
- Status
- COMPLETED
- Phase
- PHASE2
Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Epidemiology and Household Transmission of Streptococcus Pneumoniae and Respiratory Syncytial Virus
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)
- Status
- COMPLETED
- Phase
- PHASE2
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Belzutifan (MK-6482) in Participants With Hepatic Impairment (MK-6482-020)
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)
- Status
- COMPLETED
- Phase
- PHASE1
A Study of SEA-CD40 Given With Other Drugs in Cancers
- Status
- COMPLETED
- Phase
- PHASE2
Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Olinvacimab With Pembrolizumab in Patients With mTNBC
- Status
- TERMINATED
- Phase
- PHASE2
PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN
- Status
- COMPLETED
- Phase
- PHASE2